Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesAdvances in Understanding and Management of Myeloproliferative Neoplasms
CA-A Cancer Journal for Clinicians, 05/07/09
Vannucchi AM et al. - According to the 2008 World Health Organization classification system for hematologic malignancies, the myeloproliferative neoplasms (MPN) include chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, mastocytosis, chronic eosinophilic leukemia-not otherwise specified, chronic neutrophilic leukemia, and "MPN, unclassifiable.
Related Articles
Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms
British Journal of Haematology, 11/11/09
Relevance Score: 67%
AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms
Blood, 11/09/09
Relevance Score: 67%
Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells
Blood, 11/02/09
Relevance Score: 66%
Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity
Clinical Cancer Research, 11/09/09
Relevance Score: 65%
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
Annals of Oncology, 10/29/09
Relevance Score: 44%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma
International Journal of Hematology, 12/01/09
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
Blood, 12/01/09
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Clinical Cancer Research, 12/01/09
Sponsor
Article Search
Sponsor
Sponsor